IP Library Granted Patent US 12,331,319
Granted Patent B2
US 12,331,319 · App. 16/604,596 · Granted Jun 17, 2025

Respiratory and sweat gland ionocytes

Inventors: Jayaraj Rajagopal (Boston, MA); Aviv Regev (Cambridge, MA); Moshe Biton (Cambridge, MA); Adam Haber (Cambridge, MA); Daniel Montoro (Boston, MA); Orit Rozenblatt-Rosen (Cambridge, MA)
Assignees: THE BROAD INSTITUTE, INC.; THE GENERAL HOSPITAL CORPORATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
C12N5/0688A61K35/42A61P11/00G01N33/5044C12N2501/42C12N2506/27
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,319
App. No.
16/604,596
Granted
Jun 17, 2025
Kind
B2
Abstract

Provided herein are methods and compositions for identifying ionocytes from respiratory epithelial cells, and uses of such cells for treatment of inflammatory lung disease. Also provided herein are methods and compositions for modulating respiratory tract epithelial cell proliferation, differentiation, maintenance, and/or function.

Claims (8)

1. A method for increasing expression of CFTR in epithelial ionocytes, the method comprising delivering in vivo to a subject in need thereof one or more modulating agents comprising an adenovirus viral vector (AAV) comprising a polynucleotide sequence encoding FOXI1, wherein delivery of the polynucleotide sequence encoding FOXI1 increases the expression of FOXI1 and CFTR in the epithelial ionocytes.

2. The method of claim 1 , wherein the subject suffers from an inflammatory lung disease.

3. The method of claim 2 , wherein the inflammatory lung disease is asthma, bronchitis, cystic fibrosis, infection, emphysema, lung cancer, pulmonary hypertension, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, or α-1-anti-trypsin deficiency.

4. The method of claim 2 , wherein the inflammatory lung disease is cystic fibrosis.

5. The method of claim 1 , wherein the AAV is an AAV5 viral vector.

6. The method of claim 1 , wherein the viral vector is administered as an aerosol.

7. The method of claim 5 , wherein the vector comprises a deletion of base pairs 355 to 3325 to eliminate E1a and E1b functions, a deletion of base pairs 3325 to 4021 to eliminate protein IX function, and a deletion of base pairs 28592 to 30470 to eliminate E3 functions.

8. The method of claim 1 , wherein the polynucleotide sequence encoding FOXI1 comprises set forth in NCBI Reference Sequence NM_144769.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2019
From: ROZENBLATT-ROSEN, ORIT
To: THE BROAD INSTITUTE, INC.
Reel/Frame 051297/0079 →